Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Jan 30's posts. Generated by AI.
Summary of Jan 31's posts. Generated by AI.
Summary of Jan 5's posts. Generated by AI.
Investors talking about CNTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4. The company is advancing these candidates through early-stage clinical and preclinical development, with particular attention to cancers such as ovarian, endometrial, and breast cancer. Context Therapeutics Inc. operates as an oncology-focused biotechnology company and works to translate targeted immunotherapy research into potential treatments for genetically and biologically defined patient populations. Headquartered in Philadelphia, Pennsylvania, it remains centered on drug discovery and clinical development rather than commercialized products.
Website2001 Market Street
Philadelphia, PA, 19103
United States
The latest articles about CNTX.
Tipranks Press Release.
Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P